- Home
- NG vs BEAM Comparison
NG vs BEAM Comparison
Compare NG & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NG | BEAM |
|---|---|---|
| Founded | 1984 | 2017 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 2.8B |
| IPO Year | 2002 | 2019 |
Fundamental Metrics
Financial Performance| Metric | NG | BEAM |
|---|---|---|
| Price | $5.86 | $24.34 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 15 |
| Target Price | $13.13 | ★ $49.85 |
| AVG Volume (30 Days) | ★ 4.2M | 1.8M |
| Earning Date | 10-08-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 82.31 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $24,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 33.33 |
| 52 Week Low | $5.08 | $20.23 |
| 52 Week High | $14.40 | $38.26 |
Technical Indicators
Market Signals| Indicator | NG | BEAM |
|---|---|---|
| Relative Strength Index (RSI) | 41.40 | 46.00 |
| Support Level | $5.08 | $22.98 |
| Resistance Level | $6.69 | $27.30 |
| Average True Range (ATR) | 0.38 | 1.84 |
| MACD | 0.03 | -0.13 |
| Stochastic Oscillator | 15.51 | 21.19 |
Price Performance
Historical ComparisonAbout NG Novagold Resources Inc.
Novagold Resources Inc operates in the gold mining industry, focused on advancing the Donlin Gold project in Alaska. The Donlin Gold project is held by Donlin Gold LLC (Donlin Gold), a limited liability company owned equally by wholly owned subsidiaries of NOVAGOLD and Barrick Gold Corporation (Barrick). The company includes exploration and development activities of gold and other precious metals.
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.